Literature DB >> 21385563

Field flow fractionation for assessing neonatal Fc receptor and Fcγ receptor binding to monoclonal antibodies in solution.

Joey Pollastrini1, Thomas M Dillon, Pavel Bondarenko, Robert Y-T Chou.   

Abstract

Analysis of the strength and stoichiometry of immunoglobulin G (IgG) binding to neonatal Fc receptor (FcRn) and Fcγ receptor (FcγR) is important for evaluating the pharmacokinetics and effector functions of therapeutic monoclonal antibody (mAb) products, respectively. The current standard for assessing FcγR and FcRn binding is composed of cell-based and surface plasmon resonance (SPR) assays. In this work, asymmetrical flow field flow fractionation (AF4) was evaluated to establish the true stoichiometry of IgG binding in solution. AF4 and liquid chromatography-mass spectrometry (LC-MS) were applied to directly observe IgG/FcγR and IgG/FcRn complexes, which were not observed using nonequilibrium size exclusion chromatography (SEC) analysis. Human serum albumin (HSA), an abundant component of human blood and capable of binding FcRn, was studied in combination with FcRn and IgG. AF4 demonstrated that the majority of large complexes of IgG/FcRn/HSA were at an approximate 1:2:1 molar ratio. In addition, affinity measurements of the complex were performed in the sub-micromolar affinity range. A significant decrease in binding was detected for IgG molecules with increased oxidation in the Fc region. AF4 was useful in detecting weak binding between full-length IgG/Fc fragments and Fc receptors and the effect of chemical modifications on binding. AF4 is a useful technique in the assessment of mAb product quality attributes.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21385563     DOI: 10.1016/j.ab.2011.03.001

Source DB:  PubMed          Journal:  Anal Biochem        ISSN: 0003-2697            Impact factor:   3.365


  8 in total

1.  Analytical FcRn affinity chromatography for functional characterization of monoclonal antibodies.

Authors:  Tilman Schlothauer; Petra Rueger; Jan Olaf Stracke; Hubert Hertenberger; Felix Fingas; Lothar Kling; Thomas Emrich; Georg Drabner; Stefan Seeber; Johannes Auer; Stefan Koch; Apollon Papadimitriou
Journal:  MAbs       Date:  2013-05-29       Impact factor: 5.857

2.  Impact of SPR biosensor assay configuration on antibody: Neonatal Fc receptor binding data.

Authors:  Xiangdan Wang; Patrick McKay; Liliana T Yee; George Dutina; Philip E Hass; Ihsan Nijem; David Allison; Kyra J Cowan; Kevin Lin; Valerie Quarmby; Jihong Yang
Journal:  MAbs       Date:  2016-12-21       Impact factor: 5.857

Review 3.  Neonatal Fc receptor and IgG-based therapeutics.

Authors:  Timothy T Kuo; Victoria G Aveson
Journal:  MAbs       Date:  2011-09-01       Impact factor: 5.857

4.  Dissociation-based screening of nanoparticle-protein interaction via flow field-flow fractionation.

Authors:  Jonathan Ashby; Samantha Schachermeyer; Songqin Pan; Wenwan Zhong
Journal:  Anal Chem       Date:  2013-07-26       Impact factor: 6.986

Review 5.  Neonatal Fc Receptor-Targeted Therapies in Neurology.

Authors:  Christopher Nelke; Marianna Spatola; Christina B Schroeter; Heinz Wiendl; Jan D Lünemann
Journal:  Neurotherapeutics       Date:  2022-01-07       Impact factor: 6.088

6.  Study on FcγRn Electrochemical Receptor Sensor and Its Kinetics.

Authors:  Dandan Peng; Dingqiang Lu; Guangchang Pang
Journal:  Molecules       Date:  2020-07-14       Impact factor: 4.411

7.  Identification of critical chemical modifications by size exclusion chromatography of stressed antibody-target complexes with competitive binding.

Authors:  Rachel Liuqing Shi; Gang Xiao; Thomas M Dillon; Arnold McAuley; Margaret S Ricci; Pavel V Bondarenko
Journal:  MAbs       Date:  2021 Jan-Dec       Impact factor: 5.857

8.  Identification of critical chemical modifications and paratope mapping by size exclusion chromatography of stressed antibody-target complexes.

Authors:  Pavel Bondarenko; Andrew C Nichols; Gang Xiao; Rachel Liuqing Shi; Pik Kay Chan; Thomas M Dillon; Fernando Garces; David J Semin; Margaret S Ricci
Journal:  MAbs       Date:  2021 Jan-Dec       Impact factor: 5.857

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.